Equities research analysts predict that Heron Therapeutics Inc (NASDAQ:HRTX) will announce earnings per share (EPS) of ($0.82) for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Heron Therapeutics’ earnings, with estimates ranging from ($1.07) to ($0.57). Heron Therapeutics posted earnings of ($1.00) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 18%. The firm is expected to report its next earnings report on Wednesday, May 9th.
On average, analysts expect that Heron Therapeutics will report full year earnings of ($2.50) per share for the current year, with EPS estimates ranging from ($3.69) to ($1.83). For the next year, analysts anticipate that the company will report earnings of ($0.72) per share, with EPS estimates ranging from ($1.64) to $0.87. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Heron Therapeutics.
Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.29). Heron Therapeutics had a negative net margin of 641.87% and a negative return on equity of 230.70%. The company had revenue of $10.05 million for the quarter, compared to the consensus estimate of $9.00 million.
In other Heron Therapeutics news, Director Kevin C. Tang purchased 192,308 shares of the stock in a transaction that occurred on Thursday, March 29th. The stock was purchased at an average price of $26.00 per share, with a total value of $5,000,008.00. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Barry D. Quart sold 100,000 shares of the stock in a transaction dated Wednesday, March 14th. The shares were sold at an average price of $24.75, for a total transaction of $2,475,000.00. Following the completion of the transaction, the chief executive officer now directly owns 167,993 shares of the company’s stock, valued at approximately $4,157,826.75. The disclosure for this sale can be found here. In the last ninety days, insiders sold 218,000 shares of company stock valued at $5,990,000. 19.93% of the stock is owned by insiders.
Several large investors have recently made changes to their positions in the stock. Geode Capital Management LLC lifted its holdings in shares of Heron Therapeutics by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 397,456 shares of the biotechnology company’s stock valued at $7,193,000 after acquiring an additional 2,410 shares during the last quarter. Fox Run Management L.L.C. lifted its holdings in shares of Heron Therapeutics by 27.5% in the 4th quarter. Fox Run Management L.L.C. now owns 22,050 shares of the biotechnology company’s stock valued at $399,000 after acquiring an additional 4,750 shares during the last quarter. Jane Street Group LLC lifted its holdings in shares of Heron Therapeutics by 36.3% in the 4th quarter. Jane Street Group LLC now owns 18,806 shares of the biotechnology company’s stock valued at $340,000 after acquiring an additional 5,006 shares during the last quarter. Royce & Associates LP lifted its holdings in shares of Heron Therapeutics by 17.4% in the 3rd quarter. Royce & Associates LP now owns 67,500 shares of the biotechnology company’s stock valued at $1,090,000 after acquiring an additional 10,000 shares during the last quarter. Finally, Ellington Management Group LLC bought a new position in shares of Heron Therapeutics in the 4th quarter valued at about $195,000. 97.40% of the stock is owned by hedge funds and other institutional investors.
Shares of HRTX traded up $0.10 during midday trading on Friday, hitting $30.55. 1,694,329 shares of the company traded hands, compared to its average volume of 1,302,426. Heron Therapeutics has a 52 week low of $12.70 and a 52 week high of $32.70. The company has a market capitalization of $2,075.92, a PE ratio of 8.37 and a beta of 1.88.
WARNING: This news story was first reported by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://dakotafinancialnews.com/2018/04/13/zacks-brokerages-expect-heron-therapeutics-inc-hrtx-will-announce-earnings-of-0-82-per-share.html.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.